157 related articles for article (PubMed ID: 10806675)
1. [Anti-tumor effect of cytotoxic T lymphocytes induced by soluble antigen of ovarian carcinoma and anti-CD3 monoclonal antibody on ovarian carcinoma].
Zhang Q; Wan Y; Zhai H
Zhonghua Fu Chan Ke Za Zhi; 1998 Jun; 33(6):355-7. PubMed ID: 10806675
[TBL] [Abstract][Full Text] [Related]
2. In vivo antitumor activity of anti-CD3-induced activated killer cells.
Yun YS; Hargrove ME; Ting CC
Cancer Res; 1989 Sep; 49(17):4770-4. PubMed ID: 2527087
[TBL] [Abstract][Full Text] [Related]
3. Injury to autologous normal tissues and tumors mediated by lymphokine-activated killer (LAK) cells generated in vitro from peripheral blood mononuclear cells of glioblastoma patients.
Fujimiya Y; Suzuki Y; Katakura R; Ohno T
J Hematother; 1999 Feb; 8(1):29-37. PubMed ID: 10192299
[TBL] [Abstract][Full Text] [Related]
4. [Specific immune cell therapy against ovarian cancer in vivo and in vitro].
Chang XH; Cheng HY; Cheng YX; Ye X; Guo HF; Fu TY; Zhang L; Zhang G; Cui H
Ai Zheng; 2008 Dec; 27(12):1244-50. PubMed ID: 19079987
[TBL] [Abstract][Full Text] [Related]
5. [Experimental study of the anti-tumor activity of CD3AK against human gastric cancer cell line in vitro and in vivo].
Bai YF; Zhang XY; Mu ZX
Zhonghua Zhong Liu Za Zhi; 1994 Mar; 16(2):111-4. PubMed ID: 7924859
[TBL] [Abstract][Full Text] [Related]
6. CD3-CD28 costimulation as a means to avoiding T cell preactivation in bispecific monoclonal antibody-based treatment of ovarian carcinoma.
Mazzoni A; Mezzanzanica D; Jung G; Wolf H; Colnaghi MI; Canevari S
Cancer Res; 1996 Dec; 56(23):5443-9. PubMed ID: 8968099
[TBL] [Abstract][Full Text] [Related]
7. Activation of mononuclear cells to be used for hybrid monoclonal antibody-induced lysis of human ovarian carcinoma cells.
Pupa SM; Canevari S; Fontanelli R; Ménard S; Mezzanzanica D; Lanzavecchia A; Colnaghi MI
Int J Cancer; 1988 Sep; 42(3):455-9. PubMed ID: 2971021
[TBL] [Abstract][Full Text] [Related]
8. Generation propagation, and targeting of human CD4+ helper/killer T cells induced by anti-CD3 monoclonal antibody plus recombinant IL-2. An efficient strategy for adoptive tumor immunotherapy.
Nishimura T; Nakamura Y; Takeuchi Y; Tokuda Y; Iwasawa M; Kawasaki A; Okumura K; Habu S
J Immunol; 1992 Jan; 148(1):285-91. PubMed ID: 1345787
[TBL] [Abstract][Full Text] [Related]
9. Adhesion molecule-mediated signals regulate major histocompatibility complex-unrestricted and CD3/T cell receptor-triggered cytotoxicity.
Galandrini R; Albi N; Zarcone D; Grossi CE; Velardi A
Eur J Immunol; 1992 Aug; 22(8):2047-53. PubMed ID: 1379184
[TBL] [Abstract][Full Text] [Related]
10. [Effect of lymphokine activated killer from umbilical blood on human ovarian cancer in nude mouse models].
He YD; Peng ZL; Liu SL; Wang H; Pan XL
Sichuan Da Xue Xue Bao Yi Xue Ban; 2007 Sep; 38(5):810-2. PubMed ID: 17953364
[TBL] [Abstract][Full Text] [Related]
11. MUC1-specific targeting immunotherapy with bispecific antibodies: inhibition of xenografted human bile duct carcinoma growth.
Katayose Y; Kudo T; Suzuki M; Shinoda M; Saijyo S; Sakurai N; Saeki H; Fukuhara K; Imai K; Matsuno S
Cancer Res; 1996 Sep; 56(18):4205-12. PubMed ID: 8797593
[TBL] [Abstract][Full Text] [Related]
12. [The anti-pancreatic cancer efficacy of LAK cells mediated by YPC3 monoclonal antibody in vitro and in vivo].
Chen QK; Yuan SZ
Zhonghua Zhong Liu Za Zhi; 1994 Sep; 16(5):353-5. PubMed ID: 7895586
[TBL] [Abstract][Full Text] [Related]
13. Development and characterization of a bispecific single-chain antibody directed against T cells and ovarian carcinoma.
Kriangkum J; Xu B; Gervais C; Paquette D; Jacobs FA; Martin L; Suresh MR
Hybridoma; 2000 Feb; 19(1):33-41. PubMed ID: 10768839
[TBL] [Abstract][Full Text] [Related]
14. Human lymphokine-activated killer cells augment immunotherapy of human colon carcinoma xenografts with monoclonal antibody D612.
Pendurthi TK; Schlom J; Primus FJ
J Immunother (1991); 1991 Feb; 10(1):2-12. PubMed ID: 2012797
[TBL] [Abstract][Full Text] [Related]
15. Retargeting of human lymphocytes against human ovarian carcinoma cells by bispecific antibodies: from laboratory to clinic.
Mezzanzanica D; Canevari S; Colnaghi MI
Int J Clin Lab Res; 1991; 21(2):159-64. PubMed ID: 1815760
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-12 synergizes with interleukin-2 to generate lymphokine-activated killer activity in peripheral blood mononuclear cells cultured in ovarian cancer ascitic fluid.
Barton DP; Blanchard DK; Duan C; Roberts WS; Cavanagh D; DeCesare S; Djeu JY
J Soc Gynecol Investig; 1995; 2(6):762-71. PubMed ID: 9420887
[TBL] [Abstract][Full Text] [Related]
17. Potentiation of long-term-cultured lymphokine-activated killer cell cytotoxicity against small-cell lung carcinoma by anti-CD3 x anti-(tumor-associated antigen) bispecific antibody.
Azuma A; Yagita H; Okumura K; Kudoh S; Niitani H
Cancer Immunol Immunother; 1994 May; 38(5):294-8. PubMed ID: 7909278
[TBL] [Abstract][Full Text] [Related]
18. Cytotoxic cells in immunodeficient athymic mice.
Budzynski W; Radzikowski C
Immunopharmacol Immunotoxicol; 1994 Aug; 16(3):319-46. PubMed ID: 7528237
[TBL] [Abstract][Full Text] [Related]
19. A human tumor xenograft model of therapy with a bispecific monoclonal antibody targeting c-erbB-2 and CD16.
Weiner LM; Holmes M; Adams GP; LaCreta F; Watts P; Garcia de Palazzo I
Cancer Res; 1993 Jan; 53(1):94-100. PubMed ID: 8093231
[TBL] [Abstract][Full Text] [Related]
20. In vitro induction of tumor-specific human lymphocyte antigen class I-restricted CD8 cytotoxic T lymphocytes by ovarian tumor antigen-pulsed autologous dendritic cells from patients with advanced ovarian cancer.
Santin AD; Hermonat PL; Ravaggi A; Bellone S; Pecorelli S; Cannon MJ; Parham GP
Am J Obstet Gynecol; 2000 Sep; 183(3):601-9. PubMed ID: 10992180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]